Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions highlight the significance of aspirin in reducing coronary heart disease risk among individuals with elevated lipoprotein(a), particularly noting a 46% reduction linked to aspirin use. Phrases like 'excited to share' and 'transformative potential' indicate a positive tone and convey strong enthusiasm about integrating these findings into practice, showcasing the urgent relevance of the research.
Most discussions show a consensus on the potential benefits of aspirin for individuals with elevated Lp(a).
Participants express high interest in the article, prompted by its implications for heart disease prevention.
There is moderate engagement, with posts delving into the specifics of the study but not consistently exploring deeper implications.
Many believe the findings could significantly influence clinical approaches to cardiovascular risk management.
Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity matched cohort in MESA, aspirin was a/w a 46% reduction in CHD risk in ppl with Lp(a) >50 mg/dL. A
In a propensity matched cohort, aspirin use was associated with a 46% lower risk for coronary heart disease events in participants with Lp(a) >50 mg/dL without baseline #CVD. #AHAJournals @hsbhatia @Lpa_Doc @UCSDCardiology https://t.co/C4yGsQXj0G https://t.co/AgN6K5f2C3
Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del riesgo de eventos coronarios.( sub análisis estudio MESA) https://t.co/P7UyFQvrZx. @SIAC_cardio @CardiologiaSVC @siacprevent @mencardio @torresviera @adribaran https://t.co/JGbxrck0ye
Aspirin and CV Risk in Individuals With Elevated Lp(a): The Multi-Ethnic Study of Atherosclerosis #OpenAccess
☑️ Lp（a）「える・ぴー・りとる・えー」高値に対する少量アスピリン投与 Lp（a）が50 mg/dLを超える高値には、 一次予防でもアスピリンがイベントリスクを減らすかも、という報告 まずは、日本では測定がもっと普及してほしいです
Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis | Journal of the American Heart Association; https://t.co/4AJpBDSpTj @hsbhatia @nationallipid @CBallantyneMD @DanSofferSOS @lipiddoc
Lipoprotein(a) is a critical risk factor for cardiovascular disease, particularly for those with a family history. This video discusses the implications of high lipoprotein(a) and how aspirin may reduce heart disease…
Join our scientific team as we discuss the top clinical papers of February 2024, including the ARCADIA trial that evaluated apixaban for stroke prevention in patients with atrial cardiopathy. Discover insights from…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
https://t.co/N8PSRjL1fT
Heart disease is the leading cause of death in US. 1 in 5 have elevated lipoprotein(a), which is hereditary & confers risk beyond LDL-C with >50% increase in negative cardiovascular outcomes. Aspirin reduces risk (https://t.co/JfzmNbT0On) with more powerful drugs now in trials.
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
@WesleyVPAC Won't reduce levels, but shows reduction of events given some prothrombotic like properties of Lp(a). https://t.co/6H8xbwohpV
RT @ZHeart11768530: Aspirin and CV Risk in Individuals With Elevated Lp(a): The Multi-Ethnic Study of Atherosclerosis #OpenAccess
@marcfavell @Paddy_Barrett This is true, but having raised LP(a) is a different matter as it's thrombogenic and https://t.co/ueucaaxJQW
@marcfavell @Paddy_Barrett I'm referring to having raised LP(a). I know there's investigation of aspirin in this. LP(a) does its bad work by thrombosis and aspirin may well be beneficial. https://t.co/ueucaayhGu
In our study in MESA, we extended these results using Lp(a) levels in a propensity matched cohort. Aspirin was associated with a 46% reduction in risk in those with Lp(a) >50 mg/dL: https://t.co/XwGV2Gz6ak https://t.co/iaHdogRbTv
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
@ArsenaultBenoit @nationallipid Given you have publicly states you have high Lp(a), do you find data with EPA and ASA to be convincing enough to try these in your self? https://t.co/yKJ4W9rMyf https://t.co/6H8xbwohpV
@Drlipid @nationallipid @society_eas @fhpatienteurope @foundationofnla @TheFHFoundation Please weigh in on use of ASA with Lp(a) https://t.co/PwnwxMQMGo
@MartyMakary @drjohnm Nuance! What about Lpa and ASA; elevated Lpa affects 1/5 people on earth! https://t.co/3f6iJLMjX9,)%20%3E50%20mg%2FdL.
@drjohnm @Sensible__Med @johnwmcevoy What about Lp(a) and ASA? https://t.co/3f6iJLMjX9,)%20%3E50%20mg%2FdL.
@Paddy_Barrett Is there enough evidence to recommend ASA for primary prevention in patients with elevated Lp(a)? https://t.co/kMvIOEIrKu,)%20%3E50%20mg%2FdL.
RT @2patrickoconnor: @Drlipid https://t.co/kMvIOEIrKu,)%20%3E50%20mg%2FdL. Is there enough evidence to recommend ASA for primary preventio…
@Drlipid https://t.co/kMvIOEIrKu,)%20%3E50%20mg%2FdL. Is there enough evidence to recommend ASA for primary prevention in patients with elevated Lp(a)?
@MichaelAlbertMD @MichaelAlbertMD Curious your direction on aspirin since you have high Lp(a) https://t.co/3f6iJLMjX9,)%20%3E50%20mg%2FdL.
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
RT @JAHA_AHA: In a propensity matched cohort, aspirin use was associated with a 46% lower risk for coronary heart disease events in partici…
RT @JAHA_AHA: In a propensity matched cohort, aspirin use was associated with a 46% lower risk for coronary heart disease events in partici…
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
RT @JAHA_AHA: In a propensity matched cohort, aspirin use was associated with a 46% lower risk for coronary heart disease events in partici…
RT @JAHA_AHA: In a propensity matched cohort, aspirin use was associated with a 46% lower risk for coronary heart disease events in partici…
RT @JAHA_AHA: In a propensity matched cohort, aspirin use was associated with a 46% lower risk for coronary heart disease events in partici…
In a propensity matched cohort, aspirin use was associated with a 46% lower risk for coronary heart disease events in participants with Lp(a) >50 mg/dL without baseline #CVD. #AHAJournals @hsbhatia @Lpa_Doc @UCSDCardiology https://t.co/C4yGsQXj0G https://t.co/AgN6K5f2C3
RT @DrPontecarlosi: Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del ries…
Refinando uso de ASA en prevención Primaria.En pactes con Lp(a) >50 mg/dl se asoció con una reducción del 46 % del riesgo de eventos coronarios.( sub análisis estudio MESA) https://t.co/P7UyFQvrZx. @SIAC_cardio @CardiologiaSVC @siacprevent @mencardio @torresviera @adribaran https://t.co/JGbxrck0ye
Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis | Journal of the American Heart Association https://t.co/EsNTEkDFRJ
RT @KagawaECG: ☑️ Lp（a）「える・ぴー・りとる・えー」高値に対する少量アスピリン投与 Lp（a）が50 mg/dLを超える高値には、 一次予防でもアスピリンがイベントリスクを減らすかも、という報告 まずは、日本では測定がもっと普及してほしいです
RT @KagawaECG: ☑️ Lp（a）「える・ぴー・りとる・えー」高値に対する少量アスピリン投与 Lp（a）が50 mg/dLを超える高値には、 一次予防でもアスピリンがイベントリスクを減らすかも、という報告 まずは、日本では測定がもっと普及してほしいです
RT @KagawaECG: ☑️ Lp（a）「える・ぴー・りとる・えー」高値に対する少量アスピリン投与 Lp（a）が50 mg/dLを超える高値には、 一次予防でもアスピリンがイベントリスクを減らすかも、という報告 まずは、日本では測定がもっと普及してほしいです
RT @KagawaECG: ☑️ Lp（a）「える・ぴー・りとる・えー」高値に対する少量アスピリン投与 Lp（a）が50 mg/dLを超える高値には、 一次予防でもアスピリンがイベントリスクを減らすかも、という報告 まずは、日本では測定がもっと普及してほしいです
☑️ Lp（a）「える・ぴー・りとる・えー」高値に対する少量アスピリン投与 Lp（a）が50 mg/dLを超える高値には、 一次予防でもアスピリンがイベントリスクを減らすかも、という報告 まずは、日本では測定がもっと普及してほしいです
RT @LipidCNS: Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis | Jour…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @Office_j: 【Lp(a)上昇例のCHD初発をASAが抑制の可能性?/ JAHA】 米国、多人種CV１次予防例コホート内、PSマッチ2183例比較：Lp(a) 「>50」mg/dL群 [19%]では「≦50」群に比べCHD発症率が有意に高 [13.7 vs. 8…
RT @Office_j: 【Lp(a)上昇例のCHD初発をASAが抑制の可能性?/ JAHA】 米国、多人種CV１次予防例コホート内、PSマッチ2183例比較：Lp(a) 「>50」mg/dL群 [19%]では「≦50」群に比べCHD発症率が有意に高 [13.7 vs. 8…
【Lp(a)上昇例のCHD初発をASAが抑制の可能性?/ JAHA】 米国、多人種CV１次予防例コホート内、PSマッチ2183例比較：Lp(a) 「>50」mg/dL群 [19%]では「≦50」群に比べCHD発症率が有意に高 [13.7 vs. 8,9%] 。この「>50」群でASA服用に伴いCHD HRは0.54 [0.32-0.94]。 https://t.co/AHz4M0PTmH
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis | Journal of the American Heart Association; https://t.co/4AJpBDSpTj @hsbhatia @nationallipid @CBallantyneMD @DanSofferSOS @lipiddoc
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @DrDerekConnolly: In a propensity‐matched analysis, aspirin use was associated with a lower risk for CV events in patients with elevated…
In a propensity‐matched analysis, aspirin use was associated with a lower risk for CV events in patients with elevated lipoprotein(a) but without established CV disease. https://t.co/I2TBsxKwAZ https://t.co/JvAVnkqtR1
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @ZHeart11768530: Aspirin and CV Risk in Individuals With Elevated Lp(a): The Multi-Ethnic Study of Atherosclerosis #OpenAccess
RT @ZHeart11768530: Aspirin and CV Risk in Individuals With Elevated Lp(a): The Multi-Ethnic Study of Atherosclerosis #OpenAccess
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
Aspirin and CV Risk in Individuals With Elevated Lp(a): The Multi-Ethnic Study of Atherosclerosis #OpenAccess
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
RT @hsbhatia: Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity…
Excited to share our work on aspirin for primary prevention in ppl w/ elevated Lp(a) @JAHA_AHA @AHAScience In a propensity matched cohort in MESA, aspirin was a/w a 46% reduction in CHD risk in ppl with Lp(a) >50 mg/dL. A